普洛藥業(000739.SZ):合生科技預計將給公司帶來多個項目的較好的營收
格隆匯10月20日丨普洛藥業(000739.SZ)於2023年10月19日接受投資者調研,就“合生科技增資的選擇考慮是什麼?對公司未來合成生物學產業發展有何幫助?”,公司回覆稱,公司產業投資基金對合生科技進行了多輪調查,認為該公司合成生物學很有特色,對其價格判斷是基於產業化項目為主。普洛藥業在項目產業化能力上與合生科技有很強的互補性,所以決定入股。合生科技預計將給公司帶來多個項目的較好的營收。總體來説,有助於快速將公司的合成生物學產業做大做強。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.